Thermo Fisher ditches bid to acquire Qiagen as offer falls short
[MASSACHUSETTS] Thermo Fisher Scientific ended its agreement to purchase Qiagen after its tender offer for the Dutch health-care company fell short.
Only about 47 per cent of Qiagen shares were tendered, Thermo Fisher said in a statement Thursday, meaning the minimum threshold for acceptance of the proposed deal hadn't been met. Qiagen will pay Thermo Fisher a reimbursement of US$95 million, according to the statement.
Some shareholders had been seeking a higher price for Qiagen than the 43 euros (S$69.7) per share Thermo Fisher had offered. Davidson Kempner, a top investor in Qiagen, had said that a price between 48 euros and 52 euros a share was more appropriate and had urged others to reject Thermo Fisher's offer, which had been increased from an initial 39 euros.
BLOOMBERG
KEYWORDS IN THIS ARTICLE
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue